Finck Brian N
From Bioblast
| Name | Finck Brian N, PhD |
|---|---|
| Institution | Washington University in St. Louis
School of Medicine |
| Address | 660 S. Euclid
Campus Box 8031, |
| City | St. Louis |
| State/Province | Missouri (MO) |
| Country | USA |
| [email protected] | |
| Weblink | |
| O2k-Network Lab | US MO St Louis Finck BN |
Labels:
Publications
| Published | Reference | |
|---|---|---|
| Martino 2024 Am J Physiol Endocrinol Metab | 2024 | Martino MR, Habibi M, Ferguson D, Brookheart RT, Thyfault JP, Meyer GA, Lantier L, Hughey CC, Finck BN (2024) Disruption of hepatic mitochondrial pyruvate and amino acid metabolism impairs gluconeogenesis and endurance exercise capacity in mice. Am J Physiol Endocrinol Metab 326:E515-27. https://doi.org/10.1152/ajpendo.00258.2023 |
| Mousa 2023 Cell Rep | 2023 | Mousa MG, Vuppaladhadiam L, Kelly MO, Pietka T, Ek S, Shen KC, Meyer GA, Finck BN, Brookheart RT (2023) Site-1 protease inhibits mitochondrial respiration by controlling the TGF-Ξ² target gene Mss51. Cell Rep 42:112336. https://doi.org/10.1016/j.celrep.2023.112336 |
| Hegazy 2022 Biomedicines | 2022 | Hegazy L, Gill LE, Pyles KD, Kaiho C, Kchouk S, Finck BN, McCommis KS, Elgendy B (2022) Identification of novel mitochondrial pyruvate carrier inhibitors by homology modeling and pharmacophore-based virtual screening. https://doi.org/10.3390/biomedicines10020365 |
| Martino 2022 Cell Rep | 2022 | Martino MR, GutiΓ©rrez-Aguilar M, Yiew NKH, Lutkewitte AJ, Singer JM, McCommis KS, Ferguson D, Liss KHH, Yoshino J, Renkemeyer MK, Smith GI, Cho K, Fletcher JA, Klein S, Patti GJ, Burgess SC, Finck BN (2022) Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids. https://doi.org/10.1016/j.celrep.2022.110733 |
| Chambers 2021 JCI Insight | 2021 | Chambers KT, Cooper MA, Swearingen AR, Brookheart RT, Schweitzer GG, Weinheimer CJ, Kovacs A, Koves TR, Muoio DM, McCommis KS, Finck BN (2021) Myocardial Lipin 1 knockout in mice approximates cardiac effects of human LPIN1 mutations. JCI Insight 6:134340. |
| Hodges 2021 J Biol Chem | 2021 | Hodges WT, Jarasvaraparn C, Ferguson D, Griffett K, Gill LE, Chen Y, Ilagan MXG, Hegazy L, Elgendy B, Cho K, Patti GJ, McCommis KS, Finck BN (2021) Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice. J Biol Chem 298:101554. |
| McCommis 2020 Nat Metab | 2020 | McCommis KS, Kovacs A, Weinheimer CJ, Shew TM, Koves TR, Ilkayeva OR, Kamm DR, Pyles KD, King MT, Veech RL, DeBosch BJ, Muoio DM, Gross RW, Finck BN (2020) Nutritional modulation of heart failure in mitochondrial pyruvate carrier-deficient mice. Nat Metab 2:1232-47. https://doi.org/10.1038/s42255-020-00296-1 |
| Schweitzer 2019 FASEB J | 2019 | Schweitzer GG, Collier SL, Chen Z, McCommis KS, Pittman SK, Yoshino J, Matkovich SJ, Hsu FF, Chrast R, Eaton JM, Harris TE, Weihl CC, Finck BN (2019) Loss of lipin 1-mediated phosphatidic acid phosphohydrolase activity in muscle leads to skeletal myopathy in mice. FASEB J 33:652-67. |
| Chen 2018 Endocrinology | 2018 | Chen Y, McCommis KS, Ferguson D, Hall AM, Harris CA, Finck BN (2018) Inhibition of the mitochondrial pyruvate carrier by tolylfluanid. Endocrinology 159:609-21. |
| Vigueira 2017 Exp Physiol | 2017 | Vigueira PA, McCommis KS, Hodges WT, Schweitzer GG, Cole SL, Oonthonpan L, Taylor EB, McDonald WG, Kletzien RF, Colca JR, Finck BN (2017) The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Exp Physiol 102:985-99. |
| McCommis 2015 Cell Metab | 2015 | McCommis KS, Chen Z, Fu X, McDonald WG, Colca JR, Kletzien RF, Burgess SC, Finck BN (2015) Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling. Cell Metab 22:682-94. |
| Vigueira 2014 Cell Rep | 2014 | Vigueira PA, McCommis KS, Schweitzer GG, Remedi MS, Chambers KT, Fu X, McDonald WG, Cole SL, Colca JR, Kletzien RF, Burgess SC, Finck BN (2014) Mitochondrial pyruvate carrier 2 hypomorphism in mice leads to defects in glucose-stimulated insulin secretion. Cell Rep 7:2042-53. |
